<?xml version="1.0" encoding="UTF-8"?>
<p>Other compounds reported as potential anti-SARS-CoV-2 agents were those prescribed in oncology, sunitinib in combination with other antiarthrytic compoundsâ€”ruxolitinib and fedratinib. The mechanism of action includes the inhibition of enzymes involved in the clathrin-mediated endocytosis; tofacitinib is an example of drug that produces no inhibition of AAK1.</p>
